Detailed Characterization of T Cell Responses to Herpes Simplex Virus-2 in Immune Seronegative Persons
Overview
Authors
Affiliations
In 2003, we described a small cohort of subjects (n = 6) who possessed no detectable serum Abs to HSV-1 or HSV-2 and no clinical or virological evidence of mucosal HSV infection yet possessed consistently detectable HSV-specific T cell responses measured primarily by lymphoproliferative (LP) and CTL assays to whole HSV-2 Ag. We termed these persons immune seronegative (IS). This report characterizes the T cell responses in 22 IS subjects largely recruited from studies of HSV-seronegative subjects in ongoing sexual relationships with HSV-2-seropositive (HSV-2(+)) partners using pools of overlapping peptides spanning 16 immuno-prevalent HSV-2 proteins. Overall, 77% of IS subjects had HSV-specific LP responses, 85% had IFN-gamma ELISPOT responses to at least one HSV-2 peptide pool, and 55% had both LP and IFN-gamma ELISPOT responses. In some cases, IFN-gamma ELISPOT responses were in excess of 500 spot-forming cells per 10(6) PBMCs and persisted for over 5 y. Although HSV-2(+) subjects (n = 40) had frequent responses to glycoproteins and tegument and immediate-early (IE) proteins of HSV-2, T cell responses in IS subjects were directed primarily at UL39 and the IE proteins ICP4 and ICP0. These data suggest that the antigenic repertoire of T cells in IS subjects is skewed compared with that of HSV-2(+) subjects and that IS subjects had more frequent T cell responses to IE proteins and infrequent T cell responses to virion components. Understanding the mechanism(s) by which such responses are elicited may provide important insights in developing novel strategies for preventing acquisition of sexually acquired HSV-2.
Characterization of Nasal Mucosal T Cells in Horses and Their Response to Equine Herpesvirus Type 1.
Holmes C, Wagner B Viruses. 2024; 16(10).
PMID: 39459849 PMC: 11512333. DOI: 10.3390/v16101514.
Therapeutic vaccines for herpesviruses.
Cohen J J Clin Invest. 2024; 134(9).
PMID: 38690731 PMC: 11060731. DOI: 10.1172/JCI179483.
Raju Paul S, Scholzen A, Reeves P, Shepard R, Hess J, Dzeng R Front Immunol. 2023; 14:1249581.
PMID: 37885896 PMC: 10598782. DOI: 10.3389/fimmu.2023.1249581.
Can T Cells Abort SARS-CoV-2 and Other Viral Infections?.
Swadling L, Maini M Int J Mol Sci. 2023; 24(5).
PMID: 36901802 PMC: 10002440. DOI: 10.3390/ijms24054371.
Exposed seronegative: Cellular immune responses to SARS-CoV-2 in the absence of seroconversion.
Jay C, Ratcliff J, Turtle L, Goulder P, Klenerman P Front Immunol. 2023; 14:1092910.
PMID: 36776841 PMC: 9909393. DOI: 10.3389/fimmu.2023.1092910.